Will McDaid

Will McDaid's research centres on comparing the tumorigenic properties of different KRAS mutant isoforms in non-small cell lung cancer (NSCLC).

He's dedicated to pinpointing isoform-specific therapeutic vulnerabilities to amplify the effectiveness of direct KRAS inhibitors.

With a PhD from Queen's University Belfast, where he specialised in crafting polymeric nanoparticles for cancer treatment, Will brings a robust educational background to his career.

His proficiency in animal models and translational research plays a pivotal role in steering his current project, involving the design of rational drug combinations. In his research, he utilises animal and cell-based isogenic systems, cultivating cells in 3D conditions to more accurately replicate human NSCLC.

Will envisions personalised treatments, based on KRAS mutations, leading to enhanced responses and outcomes for cancer patients.